Derek T. Chalmers net worth and biography

Derek Chalmers Biography and Net Worth

Dr. Derek T. Chalmers is the co-founder, president and CEO of Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company. He also sits on the company’s board of directors.

Since Cara’s founding in 2004, Chalmers has led the company and served on the board of directors.

Prior to his work with Cara Therapeutics, Chalmers was a co-founder of drug discovery and development company, Arena Pharmaceuticals, Inc. He served as Arena’s vice president and executive director from 1997 to 2004. Previously, Dr. Chalmers worked at Neurocrine Biosciences as a group leader.

Chalmers earned his Ph.D in pharmacology from the University of Glasgow. He conducted research at the University of Michigan as a NARSAD and Fogerty International Fellow.

What is Derek T. Chalmers' net worth?: The estimated net worth of Derek T. Chalmers is at least $707,983.50 as of August 30th, 2021. Dr. Chalmers owns 1,011,405 shares of Cara Therapeutics stock worth more than $707,984 as of April 26th. This net worth evaluation does not reflect any other investments that Dr. Chalmers may own. Additionally, Dr. Chalmers receives a salary of $580,930.00 as CEO at Cara Therapeutics. Learn More about Derek T. Chalmers' net worth.
How old is Derek T. Chalmers?: Dr. Chalmers is currently 60 years old. There are 4 older executives and no younger executives at Cara Therapeutics. The oldest executive at Cara Therapeutics is Mr. Scott M. Terrillion, Chief Compliance Officer, General Counsel & Corporate Secretary, who is 61 years old. Learn More on Derek T. Chalmers' age.
What is Derek T. Chalmers' salary?: As the CEO of Cara Therapeutics, Inc., Dr. Chalmers earns $580,930.00 per year. There are 3 executives that earn more than Dr. Chalmers. The highest earning executive at Cara Therapeutics is Mr. Christopher A. Posner, President, CEO & Director, who commands a salary of $1,200,000.00 per year. Learn More on Derek T. Chalmers' salary.
How do I contact Derek T. Chalmers?: The corporate mailing address for Dr. Chalmers and other Cara Therapeutics executives is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. Cara Therapeutics can also be reached via phone at (203) 406-3700 and via email at [email protected]. Learn More on Derek T. Chalmers' contact information.
Has Derek T. Chalmers been buying or selling shares of Cara Therapeutics?: Derek T. Chalmers has not been actively trading shares of Cara Therapeutics during the past quarter. Most recently, Derek T. Chalmers sold 20,000 shares of the business's stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $15.47, for a transaction totalling $309,400.00. Following the completion of the sale, the chief executive officer now directly owns 991,405 shares of the company's stock, valued at $15,337,035.35. Learn More on Derek T. Chalmers' trading history.
Who are Cara Therapeutics' active insiders?: Cara Therapeutics' insider roster includes Derek Chalmers (CEO), Joana Goncalves (Insider), Jeffrey Ives (Director), Frederique Menzaghi (SVP), Christopher Posner (Pres), Thomas Reilly (CFO), Scott Terrillion (Insider), and Martin Vogelbaum (Director). Learn More on Cara Therapeutics' active insiders.
Are insiders buying or selling shares of Cara Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 74,015 shares worth more than $85,004.00. The most recent insider tranaction occured on April, 5th when insider Joana Goncalves sold 2,753 shares worth more than $2,284.99. Insiders at Cara Therapeutics own 4.2% of the company. Learn More about insider trades at Cara Therapeutics.
Information on this page was last updated on 4/5/2024.

Derek T. Chalmers Insider Trading History at Cara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/7/2021	Sell	20,000	$15.47	$309,400.00	991,405
8/30/2021	Sell	8,440	$14.20	$119,848.00	1,011,405
3/5/2021	Sell	3,103	$17.98	$55,791.94	953,614
2/25/2021	Sell	11,729	$19.33	$226,721.57	955,343
12/30/2020	Sell	6,078	$15.30	$92,993.40	936,593
12/28/2020	Sell	5,000	$16.00	$80,000.00	947,671
12/16/2020	Sell	5,000	$14.95	$74,750.00	928,921
12/10/2020	Sell	7,500	$15.29	$114,675.00	933,921
11/17/2020	Sell	11,799	$16.00	$188,784.00	941,421
9/3/2020	Sell	3,201	$16.00	$51,216.00	953,220
7/1/2020	Sell	5,000	$17.11	$85,550.00	961,421
6/3/2020	Sell	4,300	$16.01	$68,843.00	970,721
6/1/2020	Sell	700	$16.00	$11,200.00	970,721
5/22/2020	Sell	371	$16.00	$5,936.00	975,292
5/20/2020	Sell	1,200	$16.00	$19,200.00	975,292
5/12/2020	Sell	4,929	$16.00	$78,864.00	976,492
4/21/2020	Sell	6,348	$15.56	$98,774.88	987,769
1/2/2020	Sell	10,000	$16.05	$160,500.00	917,769
12/4/2019	Sell	10,699	$17.05	$182,417.95	918,468
12/2/2019	Sell	10,000	$25.79	$257,900.00	918,468
11/1/2019	Sell	5,000	$20.79	$103,950.00	928,468
10/1/2019	Sell	10,000	$18.28	$182,800.00	933,468
9/3/2019	Sell	5,000	$23.26	$116,300.00	943,468
8/1/2019	Sell	10,000	$23.27	$232,700.00	948,468
5/29/2019	Sell	5,528	$21.42	$118,409.76	963,996
3/1/2019	Sell	9,792	$17.04	$166,855.68	943,996
2/1/2019	Sell	20,000	$14.99	$299,800.00	953,788
1/4/2019	Sell	20,000	$13.61	$272,200.00
12/28/2018	Sell	15,825	$12.53	$198,287.25
12/28/2018	Sell	15,825	$12.53	$198,287.25	993,788
11/1/2018	Sell	20,000	$18.78	$375,600.00	991,392
10/1/2018	Sell	20,000	$23.79	$475,800.00
9/4/2018	Sell	20,000	$19.71	$394,200.00	1,031,392
7/10/2018	Sell	20,000	$20.64	$412,800.00	1,051,392
2/16/2018	Sell	5,400	$15.00	$81,000.00	1,071,392
1/24/2018	Sell	12,500	$15.00	$187,500.00	1,073,792
11/1/2017	Sell	16,000	$12.66	$202,560.00	1,066,292
7/14/2017	Sell	25,000	$15.05	$376,250.00	1,107,292
1/6/2016	Sell	12,500	$17.22	$215,250.00	1,087,292

Derek T. Chalmers Buying and Selling Activity at Cara Therapeutics

Cara Therapeutics Company Overview

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Today's Range

Now: $0.70

$0.64

$0.72

50 Day Range

MA: $0.83

$0.63

$1.05

2 Week Range

Now: $0.70

$0.50

$4.67

Volume

318,977 shs

Average Volume

344,920 shs

Market Capitalization

$38.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

Derek Chalmers Biography and Net Worth

What is Derek T. Chalmers' net worth?

How old is Derek T. Chalmers?

What is Derek T. Chalmers' salary?

How do I contact Derek T. Chalmers?

Has Derek T. Chalmers been buying or selling shares of Cara Therapeutics?

Who are Cara Therapeutics' active insiders?

Are insiders buying or selling shares of Cara Therapeutics?